Susquehanna International Group, LLP Gt Biopharma, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $1,754 - $2,558	-7,311 Reduced 34.4%	13,943 $3,000
Q2 2023 Aug 11, 2023	BUY	$0.22 - $0.55 $4,675 - $11,689	21,254 New	21,254 $6,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $58.2 $11,702 - $765,271	13,149 New	13,149 $11,000
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.11 $42,097 - $79,830	25,669 Added 136.26%	44,507 $133,000
Q1 2022 May 16, 2022	SELL	$2.6 - $3.3 $96,002 - $121,849	-36,924 Reduced 66.22%	18,838 $54,000
Q4 2021 Feb 14, 2022	BUY	$3.05 - $7.08 $28,923 - $67,139	9,483 Added 20.49%	55,762 $170,000
Q3 2021 Nov 15, 2021	BUY	$6.68 - $15.26 $309,143 - $706,217	46,279 New	46,279 $312,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $99.6M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.